CLINICAL CASE OF TERIPARATIDE USE FOR THE TREATMENT OF POSTOPERATIVE HYPOPARATHYROIDISM WITH UNCONTROLLED HYPOCALCEMIA COMBINED WITH SEVERE OSTEOPOROSIS
https://doi.org/10.14341/osteo2016337-40
Abstract
The development of postsurgical hypoparathyroidism is the most frequent complication of thyroidectomy and radical surgical procedures on the neck. Hypoparathyroidism is a disorder characterized by hypocalcemia, parathyroid hormone (PTH) deficiency, and abnormal bone remodeling. Standard treatment of hypoparathyroidism consists of oral calcium and active forms of vitamin D. However, some patients fail to achieve the normalization of calcium levels with this therapy. We present a clinical case of postsurgical hypoparathyroidism with severe clinical presentation of hypocalcaemia treated with recombinant human PTH 1-34 - teriparatide.
References
1. Bollerslev J., Rejnmark L., Marcocci C., et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015; 173(2): 1-20. doi: 10.1530/EJE-15-0628.
2. Westerdahl J., Lindblom P., Valdemarsson S., et al. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg. 2000; 135(2): 142-7.
3. Bergenfelz A., Jansson S., Martensson H., et al. Scandinavian Quality Register for Thyroid and Parathyroid Surgery: audit of surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2007; 392(4): 445-451
4. Page C., Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. J Laryngol Otol. 2007; 121: 237-241.
5. Фархутдинова Л.М., Иванова М.А., Туник В.Ф. Гипо-паратиреоз: современные представления и анализ клинического случая. Архив внутренней медицины. 2016; 3(29): 71-75. Doi: 10.20514/2226-6704-2016-6-3-71-76.
6. Орлова Е.М., Экспертный Совет Российской ассоциации эндокринологов. Федеральные клинические рекомендации по диагностике и лечению гипопаратиреоза у детей и подростков. Проблемы эндокринологии. 2014; 3: 69-74. doi: 10.14341/probl201460369-74.
7. Bilezikian I.P., Khan A., Potts J.T. Jr et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, targetorgan involvement, treatment, and challenges for future research. J Bone Miner Res. 2011; 26: 2317-2337. doi: 10.1002/jbmr.483.
8. Andrysiak-Mamos E., Zochowska E., Kazmierczyk-Puchalska A., et al. Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series. Endokrynol Pol. 2016; 67(4): 403-12. doi: 10.5603/EP.a2016.0051
9. Tachibana S., Sato S., Yokoi T., et al. Severe hypocalcemia complicated by postsurgical hypoparathyroidism and hungry bone syndrome in a patient with primary hyperparathyroidism, Graves’ disease, and acromegaly. Intern Med. 2012; 51: 1869-1873.
10. Cecchi E., Grossi F., Rossi M., et al. Severe hypocalcemia and life-threatening ventricular arrhytmias: case report and proposal of a diagnostic and therapeutic algorithm. Clin Cases Miner Bone Metab. 2015; 12: 265-268. doi: 10.11138/ccmbm/2015.12.3.265
11. Allo Miguel G., Garda Fernandez E., Martinez Diaz-Guerra G., et al. Recalcitrant hypocalcaemia in a patient with post-thyroidectomy hypoparathyroidism and Roux-en-Y gastric bypass. Obes Res Clin Pract. 2016; 10(3): 344-7. doi: 10.1016/j.orcp.2015.09.001. № 3/2016 Остеопороз и остеопатии
12. Hod T., Riella L.V., Chandraker A. Recombinant PTH therapy for severe hypoparathyroidism after kidney transplantation in pre-transplant parathyroidectomized patients: review of the literature and a case report. Clin Transplant. 2015; 29: 951-957
13. Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. Остеопороз и остеопатии. 2013; 2: 32-40.
14. Белая Ж.Е. Костноанаболическая терапия остеопороза. Актуальные эндокринологические вопросы медицины активного долголетия: сахарный диабет, ожирение, остеопороз. 2016; 26-27.
15. Brandi M.L. Hypoparathyroidism: the hormone replacement therapy is close. Expert Rev. Endocrinol. Metab. 2012; 7(3): 255-257.
16. Rejnmark L., Sikjaer T., Underbjerg L., Mosekilde L. PTH replacementtherapy of hypoparathyroidism. Osteoporos Int. 2013; 24(5): 1529-36. doi: 10.1007/s00198-012-2230-4.
17. Cusano N.E., Rubin M.R., Bilezikian J.P. Parathyre-oid hormone therapy for hypoparathyroidism. Best Pract Res Clin Endocrinol Metab. 2015 Jan; 29(1): 47-55. doi: 10.1016/j.beem.2014.09.001.
18. Rubin M.R., Sliney J., Jr, McMahon D.J., et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporosis International. 2010; 21: 1927-1934.
19. Cusano N.E., Rubin M.R., McMahon D.J., et al. Therapy of Hypoparathyroidism with PTH(1-84): A Prospective Four-Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2013; 98: 137-144. doi: 10.1210/jc.2012-2984
20. Sikjaer T., Rejnmark L., Rolighed L., et al. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26: 2358-2370. doi: 10.1002/jbmr.470.
21. Mannstadt M., Clarke B.L., Vokes T., et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013; 1: 275-283. doi: 10.1016/S2213-8587(13)70106-2.
22. Winer K.K., Ko C.W., Reynolds J.C., et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88: 4214-4220.
23. Winer K.K., Sinaii N., Reynolds J., et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol and Metab. 2010; 95: 2680-2688. doi: 10.1210/jc.2009-2464.
24. Winer K.K., Zhang B., Shrader J.A., et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trialcomparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012 Feb; 97(2): 391-9. doi: 10.1210/jc.2011-1908.
25. Gafni R.I., Brahim J.S., Andreopoulou P., et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res. 2012; 27: 1811-1820. doi: 10.1002/jbmr.1627.
26. Vahle J.L., Sato M., Long G.G., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30(3): 312-21.
27. Diaz-Soto G., Mora-Porta M., Nicolau J., et al. Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide. Horm Metab Res. 2012; 44(9): 708-10. doi: 10.1055/s-0032-1308971.
28. Anon A.O., Porta M.M., Lopez C.Q., et al. Treatment of unresponsive hypoparathyroidisn when the oral rout administration is not possible. Endocrinology and Nutrition. 2015; 62(7): 361-362.
Review
For citations:
Grebennikova T.A., Larina I.I., Belaya Zh.E., Rozhinskaya L.Y. CLINICAL CASE OF TERIPARATIDE USE FOR THE TREATMENT OF POSTOPERATIVE HYPOPARATHYROIDISM WITH UNCONTROLLED HYPOCALCEMIA COMBINED WITH SEVERE OSTEOPOROSIS. Osteoporosis and Bone Diseases. 2016;19(3):37-40. (In Russ.) https://doi.org/10.14341/osteo2016337-40
Views:
2155
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
